volume 30, issue s2, PS251-S268 2012
DOI: 10.3233/jad-2012-111376
View full text
|
|
Share
Patrick G. Kehoe, Peter A. Passmore

Abstract: There is an urgent need to improve upon Alzheimer's disease (AD) treatments. Limitations of existing drugs are that they target specific downstream neurochemical abnormalities while the upstream underlying pathology continues unchecked. Preferable treatments would be those that can target a number of the broad range of molecular and cellular abnormalities that occur in AD such as amyloid-β (Aβ) and hyperphosphorylated tau-mediated damage, inflammation, and mitochondrial dysfunction, as well more systemic abnor…

expand abstract